Gentile Pietro, Sterodimas Aris
1Department of Surgical Science, University of Rome Tor Vergata, Rome, Italy.
2Department of Plastic and Reconstructive Surgery, Metropolitan General Hospital, Athens, Greece.
Aging Dis. 2020 May 9;11(3):465-469. doi: 10.14336/AD.2020.0422. eCollection 2020 May.
A recent and interesting study reported improved respiratory activity after intravenous administration of mesenchymal stem cells (MSCs) into patients affected by coronavirus disease 2019 (COVID-19). These outcomes displayed that intravenous infiltration of MSCs is a safe and efficacy treatment for COVID-19 pneumonia, a severe acute respiratory illness caused by the coronavirus 2 (SARS-CoV-2). Only 7 patients were treated, but with extraordinary results, opening a new strategy in COVID-19 therapy. Currently, no specific therapies against SARS-CoV-2 are available. The MSCs therapy outcomes reported, are striking, as these cells inhibit the over-activation of the immune system, promoting endogenous repair, by improving the lung microenvironment after the SARS-CoV-2 infection. The MSCs could represent an effective, autologous and safe therapy, and therefore, sharing these published results, here is reported the potential use possibilities in COVID-19 of the most common MSCs represented by Adipose Stem Cells (ASCs).
最近一项有趣的研究报告称，在对2019冠状病毒病（COVID-19）患者静脉注射间充质干细胞（MSCs）后，其呼吸活动得到改善。这些结果表明，MSCs静脉注入是治疗COVID-19肺炎（一种由冠状病毒2（SARS-CoV-2）引起的严重急性呼吸道疾病）的一种安全有效的治疗方法。仅对7名患者进行了治疗，但取得了非凡的效果，为COVID-19治疗开辟了新策略。目前，尚无针对SARS-CoV-2的特异性疗法。所报告的MSCs治疗结果令人瞩目，因为这些细胞通过改善SARS-CoV-2感染后的肺微环境来抑制免疫系统的过度激活，促进内源性修复。MSCs可能代表一种有效、自体且安全的治疗方法，因此，在此分享这些已发表的结果，报告脂肪干细胞（ASCs）所代表的最常见MSCs在COVID-19中的潜在应用可能性。
